Savara Announces Senior Management Changes

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Companya??s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Companya??s Board of Directors has appointed Matthew Pauls as Chairman and Interim CEO. Mr. Pauls has served as a member of Savaraa??s Board of Directors since 2017 and is a seasoned biopharmaceutical leader with extensive experience in the rare disease sector. Taneli Jouhikainen, President and Chief Business Officer, has also resigned to pursue other opportunities.

"On behalf of the Board of Directors and the entire company, I want to thank the companya??s founders, Rob and Taneli, for their contributions to Savara and wish them well in their future endeavors,a?? said Matthew Pauls, Chairman and Interim CEO. "Importantly, moving forward, Savaraa??s highest priority is Molgradex and the initiation of the pivotal Phase 3 trial, IMPALA 2, in the first quarter of 2021. With Molgradex we have the potential opportunity to bring the first approved therapy for autoimmune pulmonary alveolar proteinosis to market. We also look forward to disclosing top line results from the Phase 3 AeroVanc AVAIL study early next year and getting regulatory feedback on the Apulmiq clinical development program.a??

About Savara

Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex (molgramostim nebulizer solution), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savaraa??s strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at (Twitter: @SavaraPharma, LinkedIn:

Forward Looking Statements
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2022    »